Retrospective analysis of invasive lobular carcinomas of the breast: Implications for diagnosis and treatment. Background: The objective of this study is to report our experience of ...

Please provide your email address to receive an email when new articles are posted on . Gonadotropin-releasing hormone analogue therapy is linked to improvement in final adult height and reduced BMI ...

Central precocious puberty (CPP) is characterised by the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, resulting in early development of secondary sexual characteristics. This ...

Men with breast cancer who were treated with Soltamox plus gonadotropin-releasing hormone analogue had a decrease in estradiol levels of 85%, whereas Aromasin plus gonadotropin-releasing hormone ...

A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA. Background: The incidence of premature ovarian ...

Please provide your email address to receive an email when new articles are posted on . Gonadotropin-releasing hormone analogue use was not associated with increased use of subsequent gender-affirming ...

A longer duration of gonadotropin-releasing hormone analogue therapy was associated with a lower bone mineral density Z-score. "Patients and providers should discuss the impact of puberty-delaying ...

ATLANTA—A longer duration of treatment with puberty-delaying medications among transgender youth is associated with lower bone mineral density, according to a new study that will be presented Sunday ...

Girls who received a ventriculoperitoneal shunt for infantile hydrocephalus had an increased risk of early puberty, particularly those with myelomeningocele and repeated shunt revisions, a ...